Company: RVRC
Filing Date: 2025-08-13
Form Type: S-1/A
Source: 0001213900-25-075747
Chunk: 85

Company: Revium Rx.
Filing Date: 2025-08-13
Form: S-1/A
Chunk 85
---
 plus liposomal) in vaginal secretions (ng/g) and plasma (ng/mL) following IP administration of Nano-mupirocin 50 mg/kg (mean ± SE). (n = 5 for swab samples and n = 4 for plasma samples).

Substantial pre-clinical research of the novel
Nanoparticles-based Mupirocin formulation has proven that this novel approach may allow for a new potent therapy to combat bacteria listed
as serious and urgent threats by the Center for Disease Control (CDC). Management believes that The novel formulation of nanoparticles-based
Mupirocin is expected to establish Mupirocin as a highly-potent systemic drug that can be used for such life-threatening infections,
such as endocarditis, osteomyelitis, or sepsis often caused by multidrug-resistant bacteria.

<div align='center'>52</div>

Novel Nanoparticles-based formulation of Mupirocin
offers several key advantages, including:

| - | Proven in vitro Antibacterial                                                                   
 Activity. The antibacterial spectrum of Mupirocin is well studied. Mupirocin is registered      
 as a topical ointment (Bactroban™ by GlaxoSmithKlein). Mupirocin is known to be highly          
 effective against staphylococci, streptococci, certain Gram-negative bacilli, including N.      
 gonorrhoea and a broad range of Gram-positive bacteria. [1] Mupirocin’s activity                
 is enhanced at acidic pH levels and is not significantly influenced by inoculum size, although  
 its effectiveness decreases in serum due to high protein binding (95%). Its primary mechanism   
 involves inhibiting RNA and protein synthesis by targeting the isoleucine-binding site on       
 the isoleucyl-transfer-RNA synthetase enzyme in bacteria. This unique mode of action, different 
 from other antibiotics, reduces the likelihood of cross-resistance.[2]                          |

| - | Nano-Mupirocin: Enhanced Spectrum                                                                   
 and Cellular Uptake                                                                                 
 Nano-formulated mupirocin has demonstrated increased efficacy in vitro and in animal models,        
 including activity against methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant 
 Enterococcus faecium (VRE), and cephalosporin-resistant Neisseria gonorrhoeae [3].                  |

| - |

| - | These                                                                                            
 formulations enhance uptake by phagocytic cells such as